Jason Ruth

Functions as a College/University

Functions as a College/University

5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments.

Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health.

Wellington Management invests in companies located in the United States. The firm targets companies operating in the fields of consumer, technology, healthcare, financial services, climate technology and biotechnology sectors. It provides financing for early stage to later stage capital requirements.

Operates as a blank check company

The private company is based in Paso Robles. The Castleman Disease Collaborative Network (CDCN) is a patient-founded nonprofit organization established in 2012 that focuses on accelerating research, improving treatment, and enhancing patient care for Castleman disease, a rare and complex group of inflammatory disorders. CDCN connects physicians, researchers, patients, and loved ones worldwide through online platforms, registries, forums, and summits to foster collaboration and scientific progress. The organization uses a community-driven approach to prioritize research questions, recruit scientists, and fund targeted studies, with a comprehensive research pipeline that includes patient enrollment, biospecimen collection, data analysis, and dissemination of findings. CDCN emphasizes drug repurposing and identification of new therapeutic targets, with clinical trials underway for treatments beyond the only FDA-approved drug for idiopathic multicentric Castleman disease. Key initiatives include the ACCELERATE natural history registry, the Castleman Disease Expert Panel, the IMCD Treatment Target Dashboard, and the Roadmap Project for drug repurposing. CDCN provides resources for patients, physicians, and researchers, such as toolkits, referral lists, support networks, educational materials, and regular updates.